JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WRIGHT, C. I.
Right arrow Articles by SABINE, J. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by WRIGHT, C. I.
Right arrow Articles by SABINE, J. C.
Journal of Pharmacology And Experimental Therapeutics, Vol. 78, Issue 4, 375-385, 1943
Copyright © 1943 by American Society for Pharmacology and Experimental Therapeutics

THE INACTIVATION OF CHOLINESTERASE BY MORPHINE, DILAUDID, CODEINE AND DESOMORPHINE

C. I. WRIGHT 1 and JEAN C. SABINE 1

1 From the Division of Chemotherapy, National Institute of Health, Bethesda, Maryland

Morphine, codeine, dilaudid, and desomorphine inhibit the activity of cholinesterase from the following sources: human, dog or rabbit serum, and human or rabbit brain. The degree of inhibition varies with the source of the enzyme, which might account for the selective action of these drugs on physiological systems. The inhibition is in part competitive and in part non-competitive, judging by the relative reaction velocity at different substrate concentrations. The affinity of the alkaloids for the enzyme in human serum is as great (dilaudid) or greater (codeine, morphine and desomorphine) than the affinity of the enzyme for acetylcholine.

Submitted on April 19, 1943






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1943 by the American Society for Pharmacology and Experimental Therapeutics.